Skip Navigation


Annals of Oncology Advance Access originally published online on June 6, 2005
Annals of Oncology 2005 16(7):1160-1168; doi:10.1093/annonc/mdi200
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/7/1160    most recent
mdi200v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (53)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hutchings, M.
Right arrow Articles by Timothy, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hutchings, M.
Right arrow Articles by Timothy, A. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma

M. Hutchings1, N. G. Mikhaeel1,*, P. A. Fields2, T. Nunan3 and A. R. Timothy1

1 Department of Clinical Oncology, 2 Department of Haematology, 3 The Clinical PET Centre, Guy's and St. Thomas’ Hospital, London, UK

* Correspondence to: Dr N. G. Mikhaeel, Department of Clinical Oncology, Lambeth Wing, St. Thomas’ Hospital, London SE1 7EH, UK. Tel: +44-(0)207-188-4219; Fax: +44-(0)207-928-9968; Email: george.mikhaeel{at}gstt.nhs.uk

Background: Long-term survival from Hodgkin lymphoma (HL) is 80–90%, but the treatment has serious late adverse effects. Modern risk-adapted treatment requires accurate assessment of the patient's prognosis. This investigation assessed the value of positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET) after two or three cycles of chemotherapy for prediction of progression-free survival (PFS) and overall survival (OS).

Patients and methods: A total of 85 patients with HL underwent FDG-PET after two or three cycles of chemotherapy. Median follow-up was 3.3 years. FDG-PET results were related to PFS and OS using Kaplan–Meier analysis. Regression analyses were employed to test for independence of established pretreatment prognostic factors.

Results: After two or three cycles of chemotherapy, 63 patients had negative FDG-PET scans, nine patients had minimal residual uptake (MRU) and 13 patients had positive scans. Three PET-negative patients and one patient from the MRU group relapsed. In the PET-positive group, nine patients progressed and two died. Survival analyses showed highly significant associations between early interim FDG-PET and PFS (P <0.0001) and OS (P <0.03). All advanced-stage patients with positive interim FDG-PET relapsed within 2 years.

Conclusion: Early interim FDG-PET is an accurate and independent predictor of PFS and OS in HL. A positive interim FDG-PET is highly predictive of relapse in advanced-stage disease.

Key words: fluorodeoxyglucose F18, Hodgkin lymphoma, positron emission tomography, prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
D. J. Sher, P. M. Mauch, A. Van Den Abbeele, A. S. LaCasce, J. Czerminski, and A. K. Ng
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy
Ann. Onc., November 1, 2009; 20(11): 1848 - 1853.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Furth, I. G. Steffen, H. Amthauer, J. Ruf, D. Misch, S. Schonberger, C. Kobe, T. Denecke, B. Stover, H. Hautzel, et al.
Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial
J. Clin. Oncol., September 10, 2009; 27(26): 4385 - 4391.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Avigdor, S. Bulvik, I. Levi, E. J. Dann, N. Shemtov, G. Perez-Avraham, A. Shimoni, A. Nagler, I. Ben-Bassat, and A. Polliack
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma
Ann. Onc., July 16, 2009; (2009) mdp271v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedeckova, A. Plutschow, H. T. Eich, M. Dietlein, A. Engert, and T. Kozak
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
Ann. Onc., July 1, 2009; 20(7): 1270 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Hutchings and S. F. Barrington
PET/CT for Therapy Response Assessment in Lymphoma
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, M. Hutchings, T. Nihashi, and H. Nagai
Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review
J. Clin. Oncol., April 10, 2009; 27(11): 1906 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Luigi Zinzani, V. Stefoni, M. Tani, S. Fanti, G. Musuraca, P. Castellucci, E. Marchi, M. Fina, V. Ambrosini, C. Pellegrini, et al.
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
J. Clin. Oncol., April 10, 2009; 27(11): 1781 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Kobe, M. Dietlein, J. Franklin, J. Markova, A. Lohri, H. Amthauer, S. Klutmann, W. H. Knapp, J. M. Zijlstra, A. Bockisch, et al.
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Blood, November 15, 2008; 112(10): 3989 - 3994.
[Abstract] [Full Text] [PDF]

Home page
 ImagingHome page
A V Martin and B Sharma
Positron emission tomography and CT in the management of lymphoma
Imaging, September 1, 2008; 20(3): 169 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Re, S. Ferrari, P. Frata, C. Pizzocaro, C. Crippa, A. Tucci, F. Facchetti, L. Grazioli, S.M. Magrini, and G. Rossi
Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study
Ann. Onc., May 1, 2008; 19(5): 951 - 957.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
R. A. Nordal
Prognostic Factors in Cancer, 3rd ed.
Am. J. Roentgenol., January 1, 2008; 190(1): W84 - W84.
[Full Text] [PDF]

Home page
 JCOHome page
R. Advani, L. Maeda, P. Lavori, A. Quon, R. Hoppe, S. Breslin, S. A. Rosenberg, and S. J. Horning
Impact of Positive Positron Emission Tomography on Prediction of Freedom From Progression After Stanford V Chemotherapy in Hodgkin's Disease
J. Clin. Oncol., September 1, 2007; 25(25): 3902 - 3907.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Gallamini, M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, C. Patti, A. Loft, F. Di Raimondo, F. D'Amore, et al.
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
J. Clin. Oncol., August 20, 2007; 25(24): 3746 - 3752.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
P. L. Zinzani, M. Tani, R. Trisolini, S. Fanti, V. Stefoni, M. Alifano, P. Castellucci, G. Musuraca, G. Dalpiaz, L. Alinari, et al.
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
Haematologica, June 1, 2007; 92(6): 771 - 777.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K Strobel, N. Schaefer, C Renner, P Veit-Haibach, D Husarik, A. Koma, and T. Hany
Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients?
Ann. Onc., April 1, 2007; 18(4): 658 - 664.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. J. Dann, R. Bar-Shalom, A. Tamir, N. Haim, M. Ben-Shachar, I. Avivi, T. Zuckerman, M. Kirschbaum, O. Goor, D. Libster, et al.
Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome
Blood, February 1, 2007; 109(3): 905 - 909.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y. L. Kasamon, R. J. Jones, and R. L. Wahl
Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. L. Zinzani, M. Tani, S. Fanti, L. Alinari, G. Musuraca, E. Marchi, V. Stefoni, P. Castellucci, M. Fina, M. Farshad, et al.
Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
Ann. Onc., August 1, 2006; 17(8): 1296 - 1300.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. E. Juweid
Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma
Hematology, January 1, 2006; 2006(1): 259 - 265.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Hutchings, A. Loft, M. Hansen, L. M. Pedersen, T. Buhl, J. Jurlander, S. Buus, S. Keiding, F. D'Amore, A.-M. Boesen, et al.
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Blood, January 1, 2006; 107(1): 52 - 59.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
A Saleem
Potential of PET in oncology and radiotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 6 - 16.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.